Medasense Biometrics

Medasense Biometrics, established in 2008, is an Israel-based medical technology firm addressing the critical need for objective pain assessment. The company was founded by Galit Zuckerman-Stark, who serves as the CEO. Zuckerman-Stark, an electrical engineer with extensive experience in high-tech and AI, identified a gap where advanced algorithms were not being applied to the field of pain management and set out to create a solution. Her background includes roles at Applied Materials and Nokia-Siemens, as well as service in the elite Israeli Defense Forces “Haman Talpiot” program.

The company's business is centered on developing and commercializing technology for clinicians to personalize and optimize pain control, particularly for patients who cannot communicate. This is crucial in operating rooms and critical care settings. Medasense operates on a B2B model, selling its devices to hospitals and healthcare providers. Its revenue is generated through the sale of its monitoring system and the associated non-invasive finger probes. The company has secured strategic distribution agreements, such as an exclusive partnership with Medtronic for distribution in Europe, to expand its market reach.

Medasense's flagship product is the PMD-200™, a patient monitor that utilizes the company's patented Nociception Level (NOL®) technology. Nociception is the body's physiological response to a painful stimulus. The system features a non-invasive finger probe that captures data from four different sensors, measuring parameters like heart rate, heart rate variability, skin conductance, and temperature. Artificial intelligence algorithms then analyze this data to generate a single, easy-to-interpret score from 0 (no pain) to 100 (extreme pain), referred to as the NOL index. This provides clinicians with an objective measure to guide the administration of analgesics, aiming to prevent both under- and over-medication and their associated complications. The PMD-200 has received significant regulatory approvals, including the CE Mark in Europe in 2017 and a De Novo marketing authorization from the U.S. FDA in February 2023, paving the way for its commercialization in the United States.

Keywords: pain monitoring, nociception, medical device, patient monitoring, artificial intelligence in healthcare, objective pain assessment, PMD-200, Nociception Level Index, NOL, MedTech, surgical technology, critical care monitoring, anesthesia technology, physiological monitoring, opioid sparing, personalized medicine, medical sensors, signal processing, FDA approved medical device, CE Mark medical device, clinical decision support, postoperative pain, Galit Zuckerman-Stark